-
Mashup Score: 1Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia - 7 month(s) ago
Venetoclax monotherapy has clinical activity and is generally well tolerated in patients with heavily pretreated AML, and BCL2 dependence and lack of BCL-XL and MCL1 dependence predicted the best response.
Source: aacrjournals.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Sam Rubinstein (@smrubinstein.bsky.social) - 8 month(s) ago
Girl dad and husband, cat daddy, fighter of plasma cell disorders, Clinical Assistant Professor of Medicine at UNC, Cubs fan, in that order
Source: Bluesky SocialCategories: Hematologists1, Latest HeadlinesTweet-
In this vein - you can also find me here: https://t.co/gfPxlmo3oy https://t.co/aik92Uz7TP
-
-
Mashup Score: 0Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma - Full Text View - ClinicalTrials.gov - 11 month(s) ago
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma – Full Text View.
Source: clinicaltrials.govCategories: Hem/Oncs, Latest HeadlinesTweet-
@calliecoombsmd @BijoyTelivala @rajshekharucms @MusaAbuSultan @DebbieMStephens @UCIrvineHealth Yep - EAA173: https://t.co/XsSZkxaJHK (Also technically QUIREDEX has OS as primary endpoint and is positive, but likely misidentified a number of active MM patients as having SMM due to not using advanced imaging)
-
-
Mashup Score: 1Spicy Slow-Roasted Salmon With Cucumbers and Feta Recipe - 1 year(s) ago
Roasting salmon low and slow in a shallow pool of olive oil guarantees that it won’t overcook — and that it’ll soak up whatever other flavors are swimming in the oil Dried chile, fennel and coriander provide a crunchy bite and sneaky heat to the buttery salmon Serve it warm or at room temperature, with cucumbers, drizzles of more spicy oil, and feta, for a little more plushness
Source: NYT CookingCategories: Hem/Oncs, Latest HeadlinesTweet-
@Dr_AmerZeidan I like this general method: https://t.co/VgLt2TvcnF
-
-
Mashup Score: 0Two cases of carfilzomib‐induced thrombotic microangiopathy successfully treated with Eculizumab in multiple myeloma - BMC Nephrology - 1 year(s) ago
Background Treatment with proteasome inhibitors like carfilzomib in patients with multiple myeloma (MM) can induce thrombotic microangiopathy (TMA) characterized by neurological symptoms, acute kidney injury, hemolysis and thrombocytopenia. Successful treatment with the monoclonal antibody eculizumab was described for these patients, but reports of ideal management and definitive treatment…
Source: BioMed CentralCategories: Hem/Oncs, Latest HeadlinesTweet-
@AaronGoodman33 @rabonour1 A consideration is eculizumab, as the mechanism of TMA due to carfilzomib may be complement mediated: https://t.co/s3Wav8OJmM
-
-
Mashup Score: 3How I approach smoldering multiple myeloma - 1 year(s) ago
Using 2 illustrative cases and critically reviewing the pertinent literature, Vaxman and Gertz discuss their approach to patients with smoldering multiple myelo
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet-
@Dr_AmerZeidan @SagarLonialMD @gotoPER Trial, if no trial observe a la @MorieGertz: https://t.co/h3ONxF8Hek
-
-
Mashup Score: 0
In multiple myeloma, severe acute kidney injury due to myeloma cast nephropathy is caused by pathogenic free light chain immunoglobulin in serum. High…
Source: www.sciencedirect.comCategories: Hematologists1, Latest HeadlinesTweet-
@Amyloid_Planet @bdermanmd @rajshekharucms @ManniMD1 @RahulBanerjeeMD @HadidiSamer @PlasmaCellPete @stuchman1 Negative RCT for HCO-HD here suggests that prob isn't helpful: https://t.co/Tee1nlmLPc Good chemo ASAP is def #1 priority, and agree vel-based tx works better/faster IRL than in those studies. That said - time is nephron, if line already in for HD I don't see a reason not to?
-
-
Mashup Score: 1
PURPOSE We report a multicenter controlled trial comparing renal recovery and tolerance profile of doublet versus triplet bortezomib-based regimens in patients with initial myeloma cast nephropathy (CN) and acute kidney injury (AKI) without need for dialysis. METHODS After symptomatic measures and high-dose dexamethasone, patients were randomly assigned to receive bortezomib plus dexamethasone…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
@rajshekharucms @BijoyTelivala @bdermanmd @Amyloid_Planet @ManniMD1 @RahulBanerjeeMD @HadidiSamer @PlasmaCellPete @stuchman1 Also agree with omitting Cy - this is the RCT, comes up a lot on consults: https://t.co/aBllgI1cYM
-
-
Mashup Score: 2Impact of Pre-transplant Therapy and Depth of Disease Response prior to Autologous Transplantation for Multiple Myeloma - 1 year(s) ago
Patients with multiple myeloma (MM), who are eligible for autologous stem cell transplantation (ASCT), typically receive a finite period of initial therapy prior to ASCT. It is not clear if patients with suboptimal (less than a partial) response to initial …
Source: PubMed Central (PMC)Categories: Hem/Oncs, Latest HeadlinesTweet-
@RahulBanerjeeMD This is decent data suggesting that deepening response doesn’t impact long term outcomes: https://t.co/pqTL3zOlxS (I know not prospective, but a prospective study of pre-auto salvage of this size is tough to implement)
-
-
Mashup Score: 1
AbstractPurpose:. For multiple myeloma, high-dose chemotherapy and autologous blood stem-cell transplantation (ASCT) followed by lenalidomide maintenance (LenMT) at 10–15 mg/day is considered standard of care. However, dose reductions due to side effects are common and median LenMT doses achieved over time may remain lower. Dose response during LenMT has never been investigated.Patients and…
Categories: Hem/Oncs, Latest HeadlinesTweet-
@ManniMD1 @BijoyTelivala @VincentRK @myelomaMD Reason it is done is that it was allowed on CALGB100104 - not sure why to be honest! There is at least some data suggesting better outcomes with higher dose maintenance len: https://t.co/06MMptcjQF
-
@AaronGoodman33 @VPrasadMDMPH Ah you’re right - few CRs but 20% response: https://t.co/FTfk7bnksJ Should stay in my lane, generally agree (relevant to myeloma I basically never use Elo)